Meet the Team...
Our success at Taran Therapeutics is a reflection of the hard work and commitment of our skilled team. We believe in harnessing diverse expertise to develop groundbreaking medical solutions. Get to know the professionals whose passion fuels our mission to enhance patient care and treatment outcomes.
Founder, CEO
Dr. Durrant has spent his entire career as a physician and a leader in the development, commercialization, and access to important medicines addressing serious conditions.
As the founder of Taran Therapeutics, he brings experience as a senior leader at several global pharmaceuticals companies, extensive end-to-end product development, launch and commercialization expertise, including 5 global blockbusters, and an unwavering commitment to patient care. He has significant biotech, operating executive and is a seasoned CEO and board member of both public and private companies.
Dr. Durrant has a deep understanding of lenzilumab and ifabotuzumab, having worked on them for 10 years as Chairman and CEO of Humanigen from January 2016 and then acquiring these assets 'free and clear' in February 2024 in a 363 sale.
He earned his medical degree from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, his DipCH from the Melbourne Academy, Australia, and his MBA from Henley Management College, Oxford, UK. He was nominated regional Entrepreneur of the Year by EY and was Elected as a Fellow of the Learned Society of Wales in 2023 and is a Professor at the Cardiff University School of Medicine.
He has authored or co-authored multiple scientific publications which have appeared in prestigious peer-reviewed medical journals and is the owner, inventor or co-inventor of dozens of patents.
Board Member
Michael Schuster Co-Founded Mesoblast Limited and Angioblast Systems Inc. in 2004. He was part of the executive management team at both companies and currently serves as the head of pharma partnering and project management at Mesoblast Limited and was previously the head of the company's investor relations outreach program.
Mr. Schuster was Executive Vice President of Global Therapeutic Programs from 2010 to 2013 and was the Director of Business Development and Vice President of Operations from 2004 to 2010.
He holds an undergraduate degree in science from Tufts University, a Master's degree in Immunology & Microbiology from New York Medical College, and an MBA from Fordham University in New York.
